DAS-181 is under clinical development by Ansun Biopharma and currently in Phase III for Coronavirus Disease 2019 (COVID-19). According to GlobalData, Phase III drugs for Coronavirus Disease 2019 (COVID-19) have a 13% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how DAS-181’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DAS-181 overview
DAS-181 is under development for the treatment of influenza A virus,H1N1 and H3N2 subtype, influenzavirus B, COVID-19 infections, and lower respiratory tract infection due to parainfluenza type 3 virus infections in immunocompromized patients. The drug candidate is a nebulized drug formulation which is administered inhalationally as a dry powder. It is a recombinant fusion protein consisting of a sialidase catalytic domain (derived from Actinomyces viscosus sialidase) and an epithelial surface-anchoring heparin-binding domain derived from the human protein amphiregulin. It was also under development for asthma, pandemic influenza, beta corona virus infections and bronchiectasis.
DAS-181 was under development for the treatment of metapneumovirus, enterovirus.
Ansun Biopharma overview
Ansun Biopharma is a biopharmaceutical company that primarily focuses on the development of innovative therapeutics to address unmet medical needs in cancer and viral infections. Its main activities focus conducting industry-leading research and developing new therapies using its expertise in sialic acid biology. The company’s lead product is DAS181, a sialidase fusion protein designed to treat viral diseases, and develops multi-modality therapeutics for the treatment of cancer. Ansun Biopharma is headquartered in San Diego, California, the US.
For a complete picture of DAS-181’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
